Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00643799 · ClinicalTrials.gov registry record · Phase 4
Safety and Efficacy of Celecoxib Versus Naproxen in the 6-month Treatment of Knee Osteoarthritis
A Phase 4 study of Osteoarthritis, Knee, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- Completed
- Registry status
- Phase 4
- Development phase
- 586
- Enrollment target
- 20
- Study locations
NCT00643799: Completed Phase 4 study of Osteoarthritis, Knee, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
NCT00643799 is a Phase 4 study of Osteoarthritis, Knee that has completed, run by Pfizer's Upjohn has merged with Mylan to form Viatris. The registered enrollment target is 586 participants, above the 492-participant average among 112 other Osteoarthritis, Knee trials with a reported enrollment target (19% higher). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00643799, a Phase 4 study of Osteoarthritis, Knee, has completed, sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 586 participants
- Enrollment target
- 20
- Study locations
Study Summary
To compare the safety and efficacy of celecoxib versus naproxen for the treatment of knee osteoarthritis
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Celecoxib
- DRUG Naproxen
Study Locations (20)
Florida
- Pfizer Investigational Site - Clearwater
- Pfizer Investigational Site - DeLand
- Pfizer Investigational Site - Jacksonville
- Pfizer Investigational Site - Miami
- Pfizer Investigational Site - Ocala
- Pfizer Investigational Site - Orlando
- Pfizer Investigational Site - Pembroke Pines
- Pfizer Investigational Site - Tampa
- Pfizer Investigational Site - Zephyrhills
California
- Pfizer Investigational Site - Buena Park
- Pfizer Investigational Site - Paramount
- Pfizer Investigational Site - Rancho Mirage
- Pfizer Investigational Site - San Diego
- Pfizer Investigational Site - San Diego
Arizona
- Pfizer Investigational Site - Phoenix
- Pfizer Investigational Site - Tempe
Alabama
- Pfizer Investigational Site - Montgomery
Colorado
- Pfizer Investigational Site - Denver
District of Columbia
- Pfizer Investigational Site - Washington D.C.
Illinois
- Pfizer Investigational Site - Rockford
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 586 participants |
| Start Date | 2004-03 |
| Est. Completion | 2005-01 |
| Phase | Phase 4 |
What the finished NCT00643799 record still lists
NCT00643799 is an interventional study that assigns participants to a tested intervention. The registered 586 participants enrollment target is mid-sized for trials with a published cap, above the 492-participant average among 112 other Osteoarthritis, Knee trials with a reported enrollment target (19% higher).
The record links to 1 condition, with Osteoarthritis, Knee appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT00643799 names 20 study sites across 7 states, led by Florida, California, Arizona.
Frequently Asked Questions
What is clinical trial NCT00643799 about?
NCT00643799 is a clinical study titled "Safety and Efficacy of Celecoxib Versus Naproxen in the 6-month Treatment of Knee Osteoarthritis". To compare the safety and efficacy of celecoxib versus naproxen for the treatment of knee osteoarthritis
What is the current status of trial NCT00643799?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 586 participants. The study started on 2004-03. Estimated completion is 2005-01.
What conditions does trial NCT00643799 study?
This clinical trial studies the following conditions: Osteoarthritis, Knee.
What interventions are being tested in trial NCT00643799?
The interventions under investigation include: Placebo (DRUG), Celecoxib (DRUG), Naproxen (DRUG).
Who is sponsoring clinical trial NCT00643799?
This trial is sponsored by Pfizer's Upjohn has merged with Mylan to form Viatris, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00643799 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Osteoarthritis, Knee
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00643799's enrollment target sits among peer trials
586 17th of 112 higher than 96 of 112 other Osteoarthritis, Knee trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Osteoarthritis, Knee trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Triamcinolone Ketorolac (TriKe) Knee Trial
RECRUITING · Phase 4
-
Knee Osteoarthritis Treatment With Zilretta vs. Kenalog in the Context of Type II Diabetes
RECRUITING · Phase 4
-
ZYNRELEF for Pain Management in Total Knee Arthroplasty
RECRUITING · Phase 4
-
Reducing Perioperative Oxidative Stress to Prevent Postoperative Chronic Pain Following Total Knee Arthroplasty
RECRUITING · Phase 4
-
Study of Nonsteroidal Anti-inflammatory Drugs in People With Painful Knee Osteoarthritis
ACTIVE NOT RECRUITING · Phase 4
-
Corticosteroid Meniscectomy Randomized Trial
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04134260 · 586 participants · Phase 3
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
- NCT06100770 · 586 participants
Aveir AR Coverage With Evidence Development (CED) Study
- NCT06183281 · 586 participants · NA
Integrating Nonpharmacologic Strategies for Pain With Inclusion, Respect, and Equity
- NCT06976203 · 586 participants · Phase 3
A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheimer's Disease (MINDSET 2)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia